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Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment 
of B-cell Precursor Acute Lymphoblastic Leukemia 
 
by Kamron Lotfi 
 
Introduction 
Acute lymphoblastic leukemia (ALL) is a common type of adolescent and young adult 
leukemia in the United States (U.S.). Patients who are refractory or relapsed after receiving two 
or more lines of systemic therapy have the option of taking tisagenlecleucel. Due to the high cost 
of this treatment, a cost-effectiveness analysis was performed to assess the treatments for 
tisagenlecleucel, clofarabine combination, and blinatumomab. 
Objectives 
The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel; 
clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapse-
refractory ALL for adolescents and young adults from the U.S. health care payer perspective.  
Material and Methods 
Clinical data were collected from the FDA databases, RedBook online, National 
Institutes of Health (NIH) research database, PubMed database, and clinicaltrials.gov. The cost 
information was extracted from the Redbook and published studies. The cost-effective analysis 
was performed using TreeAge Pro (Healthcare Version) version 2021.  
Results 
 The incremental cost of tisagenlecleucel was $520,050 compared to blinatumomab. The 
base case showed tisagenlecleucel effectiveness was the highest at 19.284, and blinatumomab 
effectiveness was 12.580. Tisagenlecleucel had an ICER of $77,573. The probability sensitivity 
 V 
analysis showed that tisagenlecleucel was 63.1% of the time, and clofarabine combination was 
dominated by tisagenlecleucel and blinatumomab.  
Conclusions 
Tisagenlecleucel and blinatumomab dominated the clofarabine combination. According 
to the results of the sensitivity analysis, tisagenlecleucel was more cost-effective 63.1% of the 
time. Blinatumomab was more cost-effective at a lower WTP and 35.8% of the time.   
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In the past decade, breakthroughs in cancer drug research of the human immune system 
resulted in the development of a new category of cancer drugs called immunotherapy. There are 
different types of immunotherapy cancer treatments, including immune checkpoint inhibitors, T-
cell transfer therapy, monoclonal antibodies, treatment vaccines, and immune system 
modulators.1,2 Immunotherapy drugs are enhanced to target specific checkpoints in the immune 
system and the body's defense systems to tackle the most challenging oncology diseases.3,4 
However, the advancement of immunotherapy still has significant obstacles, including the need 
for biomarkers, deficiencies of clinical design to assess safety and efficacy, the incapability to 
predict the response of treatment for individual patients, and high cost.5,6 The cost of cancer 
immunotherapy is $100,000 or more per patient, roughly two times the United States median 
household annual income.7,8 Even though immunotherapy is often covered by health insurance, it 
can still be unaffordable to patients due to high out-of-pocket costs.  
Non-Hodgkin lymphoma (NHL) starts inside white blood cells called lymphocytes that 
can grow in areas of the immune system, such as the lymph nodes.9 NHL accounts for an 
estimate of 3% for cancer-related deaths and is the seventh leading cause of new cancer cases in 
the United States.10 In 2020, there were 74,200 diagnosed NHL cases and 19,970 deaths from 
this disease.11  
Acute lymphoblastic leukemia (ALL) is one of the most common types of cancer in the 
white blood cells by overproducing immature lymphocytes in the bone marrow diagnosed in the 
pediatric population.12 Children who have ALL have a high number of 
lymphoblasts/lymphocytes. When this occurs, the number of cancerous cells outnumber the 
 2 
number of white blood cells. ALL is a B-cell lymphoma disease that occurs from somatic genetic 
alterations, which include chromosome number change/rearrangement.13 Symptoms of ALL are 
anemia, bruising, bleeding, and fatigue. ALL is the most common cancer in children and young 
adults, with around 54.3% of new cases under 20.14 ALL accounts for around 20% of pediatric 
cancer for children.15 ALL occurs mainly in children, representing 80% of cases; however, adults 
can be susceptible to this disease with a low cure rate of 40%.26  According to the National 
Cancer Institute, there were over 6,100 new cases of ALL and 1,500 deaths in 2020 in the US.17  
Treatment can bring 95% complete remission of patients, and since 1948, there has been 
a significant 80% increase in survival rate in children.18,19 However, the survival rate can 
drastically decrease on patients who do not respond to initial chemotherapy treatment. 
 Adolescent or young adults with standard-risk ALL often receive three drugs for the first 
month of treatment as first-line therapy. Patients with standard-risk ALL would typically receive 
the chemotherapy drugs L-asparaginase and vincristine and the steroid drug dexamethasone.20,21 
Treatment will vary according to the cancer risk. Patients who are relapsed or refractory need to 
use a second-line therapy that consists of chemotherapies such as blinatumomab and clofarabine 
combination (etoposide and cyclophosphamide).22 Patients who are refractory or relapsed after 
receiving two or more lines of systemic therapy can use tisagenlecleucel that is considered the 
last treatment option.  
Tisagenlecleucel is indicated for adult patients with relapsed or refractory large B-cell 
lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma 
(DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from 
follicular lymphoma.23,24 Tisagenlecleucel was also approved for relapsed or refractory acute 
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lymphoblastic leukemia and for treating pediatric and young adult patients up to 25 years of age 
with B-cell acute lymphoblastic leukemia (ALL).25,26 Tisagenlecleucel is given as a single dose 
with a wholesale acquisition cost (WAC) of $475,000.27 Despite the high cost of new ALL 
treatments, studies assessing their cost-effectiveness are lacking.  
Cost-effective analysis of tisagenlecleucel compared to other salvage chemotherapy 
treatments for relapsed-refractory ALL has not been published. Due to the limitation of clinical 
trials and the high cost of CAR T-cell therapies, questions have been raised on their economic 




The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel; 
clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapse-
refractory ALL for adolescent and young adult patients from the U.S. health care payer 
perspective.   
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3. HYPOTHESIS 
 We hypothesize that tisagenlecleucel is the most cost-effective alternative for treating RR-
ALL for adolescent and young adult patients.  
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4. MATERIALS AND METHODS 
4.1. Data Sources 
Clinical data were collected from the FDA databases, RedBook online, National 
Institutes of Health (NIH) research database, PubMed database, and ClinicalTrials.gov.29,30 
ClinicalTrails.gov is managed by the United States National Library of Medicine and the 
National Institutes of Health. ClinicalTrials.gov includes information from over 200 countries, 
with more than 329,000 trials to date.31  
Tisagenlecleucel and salvage chemotherapy treatment AWP and WAC data were 
collected from the RedBook online. The information in the RedBook includes the name of the 
product, active ingredient, brand or generic status, price start date, orange book code, 
formulation, route of administration, dosage unit, average wholesale price (AWP), and wholesale 
acquisition cost (WAC).32 Drug manufacturers report the AWP and the WAC. These prices do 
not represent the actual net acquisition cost paid in the U.S. but are used for pharmacy 
reimbursement purposes. Other cost information was collected from previously published 
studies. 
4.2 Methods  
4.3 Partitioned Survival Model 
A cost-effectiveness model using the U.S. health care payer's perspective was constructed 
by using TreeAge Pro (Healthcare Version) version 2021 software. The partitioned survival 
model (Figure 1) will consist of a cohort for specific states: remission, refractory or relapsed, and 











Figure 1. States of the partitioned survival model 
The partitioned survival model baseline assumptions are that patients had a previous 
history of chemotherapy and enter the model at ten years of age. The primary study outcome was 
the number of life-years gained over the study time horizon. The incremental life-years gained 
were estimated as the difference in life-years gained between the therapeutic alternatives.  
The study includes direct healthcare costs related to the alternatives. Indirect costs were 
excluded from the analysis. All costs were adjusted to 2020 U.S. dollars using all urban 
consumers, not seasonally adjusted, U.S. city average, all items, consumer price index (CPI). 






The cost and life-years gained over the time horizon were estimated for each treatment. A 
cost-effectiveness ratio (CER) was employed to calculate the cost per life-year gained for each 
treatment alternative. The lowest cost per life-year treatment was considered as the reference 
therapy. When a treatment had a greater cost and effectiveness in relation to the reference, an 
incremental cost-effectiveness ratio was performed to determine the additional cost to obtain one 
life-year.  
The impact of parameter uncertainty was explored by a one-way sensitivity analysis on 
each model parameter. A probabilistic sensitivity analysis was conducted to investigate the 
combined impact of uncertainty of the variables included in the analysis. Random values were 
drawn from the chosen distributions as a second-order Monte-Carlo simulation of 1000 patients 
to estimate the mean and 95% confidential intervals (CI) of overall survival probabilities. All 
parameters in the model will have correspondingly appropriate distributions. Costs were 
randomly drawn from a gamma distribution; the hazard ratio was randomly sampled from a 
lognormal distribution. Likewise, binominal data, such as adverse events, were randomly drawn 
from a beta distribution.   
 
4.4. Treatment Strategies 
The FDA approved three products approved by the FDA for the treatment of ALL in 





Table 1. Tisagenlecleucel, blinatumomab, and clofarabine FDA-Approved Indications 
Generic Name  
(Approval Date) 
Pediatric ALL Indications 
Tisagenlecleucel 
(August 30, 2017) 
Indicated for the treatment of Pediatric and Young Adult Relapsed or 
Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) patients 
up to 25 years of age with B-cell precursor acute lymphoblastic 
leukemia (ALL) that is refractory or in second or later relapse. 
Blinatumomab 
(September 1, 2016) 
Indicated for the treatment of relapsed or refractory CD19-positive B-
cell precursor acute lymphoblastic leukemia (ALL) in adults and 
children. 
Clofarabine 
(December 12, 2004) 
Indicated for the treatment of pediatric patients 1 to 21 years old with 
relapsed or refractory acute lymphoblastic leukemia after at least two 
prior regimens. This indication is based upon response rate. There are no 
trials verifying an improvement in disease-related symptoms or 
increased survival with clofarabine injection. 
 
The treatment dosages for tisagenlecleucel, blinatumomab, and clofarabine are described 
in Table 2. 
Tisagenlecleucel Treatment Process 
To prepare tisagenlecleucel, the patient undergoes leukapheresis to obtain peripheral 
blood mononuclear cells. Leukapheresis treatment lasts 3 to 6 hours, and within 24 hours, the 
blood cells are cryopreserved (Table 3).32 Ex vivo preparation is next conducted for 
tisagenlecleucel with autologous T cells. The autologous T cells are transduced to activate T 
cells by a lentiviral vector. The process of preparing tisagenlecleucel takes approximately 45 
days, and during this time, patients undergo bridging therapy to stop disease progression.32 
Lymphodepleting chemotherapy is received by patients two weeks before the infusion of 
tisagenlecleucel so the patient can help the proliferation of tisagenlecleucel throughout the body. 
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Table 2. Treatment dosages for tisagenlecleucel, blinatumomab, and clofarabine 
Name Therapy Source 
Tisagenlecleucel 3.1x106/kg (0.2-5.4 x 106/kg) transfused viable T 
cells. 
Maude et al. (2018) 
Bridging 
chemotherapy  
(Given to 87% of 
patients prior to 
CART) 
Methotrexate (15mg I.T. x1); Hydrocortisone (15mg 
I.T. x1) and cytarabine (30mg I.T. weekly until CSF 
clears) 
Cytarabine (300mg/ m2 IV x 1) and etoposide 
(150mg/ m2 IV x 2) peg asparaginase (25000 units/ 
m2 IV x 1) 




to 96% of patients 
prior to CART) 
Fludarabine (30mg/ m2 IV x 4), Cyclophosphamide 
(500mg/ m2 IV x 2) 




to 4% of patients 
prior to CART) 
Cytarabine (500mg/ m2 IV x 2) and etoposide 
(150mg/m2 IV x 3) 
Maude et al. (2018) 




clofarabine (400mg/ m2 IV x 9days), etoposide 
(100mg / m2 IV X 9 days), cyclophosphamide 
(440mg / m2 x 9 days) 
Hijiya et al. (2009) 
 
 




Methotrexate (15mg I.T. x1); Hydrocortisone 
(15mg I.T. x1) and cytarabine (30mg I.T. 
weekly until CSF clears); Cytarabine (300mg/ 
m2 IV x 1) and etoposide (150mg/m2 IV x 2) 
peg asparaginase (25000 units/ m2 IV x 1) 
Lymphodepleting chemotherapy 
Days 3-17 
   
Fludarabine (30mg/ m2 IV x 4), 
Cyclophosphamide(500mg/ m2 IV x 2) 
Tisagenlecleucel 
Day 20 
3.1x106/kg (0.2-5.4 x 106/kg) transfused viable 
T cells. 
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Blinatumomab and Clofarabine combination 
 Patients who receive blinatumomab and clofarabine and are in remission also receive 
post-induction chemotherapy after one year to continue to be in remission (Tables 4 and 5).  
Table 4. Treatment timeline for blinatumomab 
Cycle Dosage 







14-day treatment-free interval 





14-day treatment-free interval 





14-day treatment-free interval 





56-day treatment-free interval 
 
Table 5. Treatment timeline for clofarabine combination 
Cycle Dosage 
Cycle 1 (9 consecutive days) clofarabine (400mg/ m2 IV x 9days), 
etoposide (100mg / m2 IV X 9 days), 
cyclophosphamide (440mg / m2 x 9 days) 
Cycle 2 (9 consecutive days) clofarabine (400mg/ m2 IV x 9days), 
etoposide (100mg / m2 IV X 9 days), 




Survival data were derived from three clinical trial sources Hijiya et al. (2009), Lin et al. 
(2018), Stackelberg et al. (2016), a study assessing the survival of ALL patients in the 10-14 
years old range and survival for the general population33. 
Tisagenlecleucel overall survival, continued remission, and event-free survival were 
obtained from Maude et al. (2018).  There were two sets of data used for tisagenlecleucel: 
• Efficacy analysis set: Includes patients that used the drug and excludes patients that 
were enrolled in the study but did not qualify for getting the drug because of death, 
changes in health status that resulted in exclusion, or problems manufacturing the drug. 
• Enrolled set: includes all the patients enrolled in the clinical trial. 
Blinatumomab clinical trial overall survival, continued remission, and event-free survival were 
obtained from Stackelberg et al. (2016). Clofarabine combination clinical trial overall survival 
curve, continued remission, and event-free survival were obtained from Hijiya et al. (2009).  
Kaplan-Meier curves were created for the probability of overall survival, continued 
remission, and event-free survival for tisagenlecleucel, blinatumomab, and clofarabine. Kaplan-
Meier curves were created because the estimates of survival data can deal with differing survival 
times since not all patients continue throughout the whole study. Also, Kaplan-Meier curves give 
a "time to an event" at the respective time interval. 
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4.6 Adverse Events 
The probability and cost of adverse events were collected from the literature (Table 6).  
 
Table 6. Cost and probabilities per patient for all treatment strategies.12,14,24 











Acute Kidney Injury 0.08 0 0.16 $682.03  
ALT or AST Increased  0.1 0.16 0.4 $1,544.79  
Anemia  0.4 0.36 0.64 $4,526.60  
Coagulopathy  0 0 0.12 $296.53  
Cytokine Release Syndrome  0.46 0.06 0 $9,043.81  
Decreased Appetite  0.09 0 0.2 $445.90  
Febrile Neutropenia 0.35 0.17 0.6 $7,273.80  
Fluid Overload 0.05 0 0 $30.02  
Gingival Bleeding 0 0 0.12 $154.67  
Hepatomegaly 0 0 0 $0   
Hyperbilirubinemia 0.11 0 0.12 $209.23  
Hypertension 0 0.06 0 $41.16  
Hypokalemia 0.08 0.17 0.36 $1,322.66  
Hypophosphatemia 0.08 0 0.12 $306.26  
Hypotension 0.17 0 0.24 $818.76  
Hypoxia 0.11 0 0 $98.97  
Increased Lipase 0 0 0.2 $275.98  
Leukopenia 0.12 0.1 0.16 $286.82  
Nausea 0 0 0.12 $111.64  
Neutropenia 0.04 0.17 0.52 $4,279.79  
Overall Neurological Events 0.13 0.04 0 $323.20  
Pleural Effusion 0.04 0 0 $51.27  
Pulmonary Edema 0.06 0 0.12 $192.22  
Pyrexia 0.1 0.14 0.16 $260.28  
Rash 0 0 0 $0  
Respiratory Distress 0.04 0.01 0 $13.34  
Thrombocytopenia 0.05 0.21 0.64 $4,416.20  
Typhilis 0 0 0.12 $60.01  




 Costs were acquired from the Red Book, Centers for Medicare and Medicaid Services, 
and adjusted to 2020 dollars by the consumer price index (CPI). The direct medical costs include 
drug administration, drug product, follow-up care, and adverse events (Tables 7-11).  
Table 7. Tisagenlecleucel healthcare costs 
Pre-tisagenlecleucel  Cost Source 
Bridging chemotherapy Drug and administration at 
the hospital 
$15,000.00 Lin et al. (2018) 
Lymphodepleting chemotherapy 
(fludarabine and 
cyclophosphamide) 96% patients 
Drug and administration at 
hospital 
$1,781.49 CMS (2018) 
Lymphodepleting chemotherapy 
(cytarabine and etoposide) 4% of 
patients 
Drug and administration at 
the hospital 
$807.78 CMS (2018) 
Treatment cost Drug $475,000.00 Red Book (2021) 
Adverse events $42,769.98 CMS (2018) 
IVIG treatment $28,818.24 Red Book (2018); 
Lin et al. (2018) 
Drug Administration at 
hospital 
$6,331.28 CMS (2018);  
Lin et al.(2018) 
Health care costs after 
treatment per month 
$8,056.01  
Total Cost  $578,564.78  
 
 
Table 8. Clofarabine combination healthcare costs 
  Cost Source 
Treatment Cost Drug $37,400.00 Lin et al. (2018) 
Adverse events $54,252.52 Lin et al. (2018); 
CMS (2018) 
Administration at hospital $24,342.68 Lin et al. (2018) 
Health care costs after 
treatment per month 
$1,964.88 Lin et al. (2018) 
Total Cost  $117,960.08  
 
 15 
Table 9. Blinatumomab healthcare costs. 
 
  Cost Source 
Treatment Cost Drug $43,700.00 Lin et al. (2018) 
Adverse events $16,919.80 Lin et al. (2018); CMS (2018) 
Administration at 
hospital 
$8,187.00 Lin et al. (2018) 
Total Cost  $68,806.80  
  
 
Table 10. Cost of palliative chemotherapy for relapsed/refractory patients. 
 
  Cost Source 
Palliative Chemotherapy Drug $2,881.82 Lin et al. 
 
 
Table 11. Cost of individual grade 3-4 adverse events for each treatment strategy. 
 






Acute Kidney Injury $1,706.04  $0  $3,412.08  
ALT or AST Increased $790.21  $1,264.33  $3,160.84  
Anemia $2,591.02  $2,331.92  $4,145.63  
Coagulopathy $0    $0   $2,472.47  
Cytokine Release Syndrome $19,342.28  $2,522.91  $0   
Decreased Appetite $834.78  $0  $1,855.07  
Febrile Neutropenia $4,980.92  $2,419.30  $8,538.71  
Fluid Overload $600.65 $0 $0 
Gingival Bleeding $0   $0 $1,289.62  
Hepatomegaly $0 $0 $0  
Hyperbilirubinemia $868.99  $0 $947.99  
Hypertension $0 $686.40  $0   
Hypokalemia $642.04  $1,364.33  $2,889.16  
Hypophosphatemia $1,178.58  $0 $1,767.87  
Hypotension $1,610.02  $0 $2,272.97  
Hypoxia $900.21  $0 $0   
Increased Lipase $0    $0 $1,380.66  




Table 11. Cost of individual grade 3-4 adverse events for each treatment strategy (Cont.) 
Nausea $0   $0  $930.83  
Neutropenia $569.25  $2,419.30  $7,400.22  
Overall Neurological Events $2,272.37  $699.19  $0    
Pleural Effusion $1,282.46  $0 $0 
Pulmonary Edema $641.07  $0   $1,282.15  
Pyrexia $471.79  $660.51  $754.86  
Rash $0  $0    $0    
Respiratory Distress $313.94  $78.49  $0 
Thrombocytopenia $484.29  $2,034.01  $6,198.89  
Typhilis $0   $0    $500.39  
Veno Occlusive Disease $0 $0 $2,163.20  





5.1 Patient Characteristics 
          The patient characteristics varied according to the clinical trial. Tisagenlecleucel patients 
were between 3 to 21 years of age (Table 12). There were 47% females and 53% males in the 
clinical trial. There were 92 patients enrolled in the study, and 75 underwent infusion 
 
Table 12. Patient population of tisagenlecleucel clinical trial data (ELIANA).12 







0-45 days before receiving 
tisagenlecleucel  
   
Dropout/Censored - 10 (11) - 
Death - 7 (8) - 
After receiving tisagenlecleucel    
Dropout/Censored - - 16 (21) 
Death - - 11 (15) 
Age, years    




Female - - 35 (47) 




Relapse/Refractory - - 9 (12) 
Remission - - 61 (81) 




Table 13. Patient population of blinatumomab clinical trials (n=70). 24 
 
Variable n (%) 
Sex  
Male 47 (67) 
Female 25(33) 
Age group, years 
 
<2 10 (14) 
2 to 6 20 (29) 
7 to 17 40 (57) 
Prevous HSCT 
 
Yes 40 (57) 
No 30 (43) 
Previous Relapses 
 
0 2 (3) 
1 31 (44) 
2 29 (41) 
 
≥ 3 8 (11) 
Status 
 
Relapse/Refractory 39 (56) 
Remission 27 (39) 
Dropout/Censored 16 (23) 
Death 27 (39) 
 
 
Blinatumomab patient age range was less than 2 years to 17 years (Table 13). The patient 
population of blinatumomab was 67% male and 33% female, with 70 total patients enrolled. 
Clofarabine combination patients were between 1 year to 21 years of age (Table 14). The patient 
population was 64% male and 36% female, with 25 patients enrolled. 
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Table 14. Patient population of clofarabine with etoposide and  
cyclophosphamide clinical trials (N=25).12 




Range 1 to 21 
Sex 
 
Male 16 (64) 




Range 1 to 3 
1 regimen 4 (16) 
2 regimen 14 (56) 
3 regimen 15 (60) 
Status 
 
Relapse/Refractory 15 (60) 
Remission 7 (28) 
Prior HSCT 4 (16) 
Dropout/Censored 2 (8) 






 Tisagenlecleucel Kaplan-Meier plot (Figure 2) 95% confidence interval at month 26 was 
0.421[0.203, 0.626]. Blinatumomab Kaplan-Meier plot (Figure 3) 95% confidence interval at 
month 26 was 0.246[0.146, 0.359]. Clofarabine combination (Figure 4) 95% confidence interval 
at month 36 was 0.211[0.0533, 0.439]. The partitioned model survival curves are displayed in 
figures 5-7. 
 










Figure 4. Clofarabine overall patient survival.12 
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5.3. Cost-Effectiveness and Incremental Cost-Effectiveness 
 
In the base case scenario, tisagenlecleucel effectiveness was 19.284 years, blinatumomab 
was 12.580 years, and clofarabine combination was 7.566 years. Blinatumomab and 
tisagenlecleucel were both undominated, and the clofarabine combination was dominated (Table 
15). 
A partitioned survival analysis model followed the patient cohort thought time as they 
moved through relapsed/refractory or remission states for tisagenlecleucel, blinatumomab, and 
clofarabine combination. The cost-effectiveness analysis showed that clofarabine was not cost-




Table 15. Incremental cost, incremental effectiveness, ICER for tisagenlecleucel, 
blinatumomab, and clofarabine combination 
 






Blinatumomab $71,701  12.580   
Tisagenlecleucel  $591,751 $520,050 19.284 6.704 $77,573 
All Therapies 
Blinatumomab $71,701  12.580   
Clofarabine $139,225 $67,524 7.566 -5.014 -$13,467 











5.4 Probabilistic Sensitivity Analysis 
 
 The PSA was conducted using the 95% confidence intervals for the overall survival and 
remission for all treatments. Clofarabine was dominated while tisagenlecleucel and 
blinatumomab remained the strategy with the higher cost and effectiveness. The PSA found that 
tisagenlecleucel was more cost-effective 63.1% and blinatumomab 35.8% of the time. 
The PSA results found that tisagenlecleucel and blinatumomab were both undominated, 
and clofarabine combination was dominated. The PSA found that tisagenlecleucel was cost-
effective 63.1% of the time with a willingness to pay $100,000. Even though tisagenlecleucel 
was more cost-effective, blinatumomab was more cost-effective 35.8% of the time (Figure 9-12).  
 The Monte Carlo acceptability at the WTP of 100,000 showed that tisagenlecleucel was 
more cost-effective 63.1% of the time when compared to blinatumomab (35.8%) and clofarabine 
(1.9%) (Figure 13). According to the cost-effectiveness acceptability curve for the WTP, 
tisagenlecleucel was more favorable at a WTP higher than $80,000. The blinatumomab WTP 










Figure 10. One-way cost-effectiveness sensitivity analysis of blinatumomab 
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  Our analysis indicates that tisagenlecleucel has higher overall survival than 
blinatumomab and clofarabine combination in patients with ALL.  
This study presented that the effectiveness for tisagenlecleucel was 19.284 and had an 
ICER of $77,573 for an additional L.Y. gained. Blinatumomab had an effectiveness of 12.580, 
and the dominated treatment clofarabine had an effectiveness of 7.566.  Tisagenlecleucel had the 
highest cost in the partitioned survival model, with $591,751 and an ICER of $77,573.  
Tisagenlecleucel and blinatumomab were both undominated, and the clofarabine 
combination was dominated for the base case analysis. The probabilistic sensitivity analysis 
confirmed that tisagenlecleucel and blinatumomab were undominated, and the clofarabine 
combination was dominated. 
According to the probabilistic sensitivity analysis, tisagenlecleucel was the most cost-
effective alternatives 63.1% of the time. These results are similar to those of other studies that 
also found that tisagenlecleucel was more cost-effective the majority of the time (Furzer et al., 
2020). Clofarabine was dominated by tisagenlecleucel and blinatumomab and was the least cost-
effective as found in previously published studies (Locatelli et al, 2009). 
  
The available evidence about the cost, efficacy, and safety of tisagenlecleucel, 
blinatumomab and clofarabine is very limited. There is a need for more studies evaluating the 
long-term effect of the available therapies for the treatment of ALL to get the evidence necessary 






This study has some limitations. The model evaluates differences of alternative therapy 
pathways from a set of assumptions and does not portray the progression of RR-ALL patients in 
clinical practice. Patients can develop RR-ALL during their lifetime. The available data only 
contains outcomes for up to 34 months. Since the clinical trials are still ongoing, other clinical 
information on outcomes and safety was collected from published studies from the United States 
and other countries. The clinical trials used in this study had different disease states, previous 
treatments, and patient demographic characteristics. The difference is significant for age because 
survival rates decline with the increase in age.30 
 
The patient characteristics included in this study were different for the clinical trials of 
the products tisagenlecleucel, blinatumomab, and clofarabine. The clinical trials for 
blinatumomab and clofarabine included patients less than 2 years of age, unlike while the clinical 
trials for tisagenlecleucel included patients starting at 3 years of age. The disease states of the 
patients included in the clinical trials were also different, with tisagenlecleucel clinical trials 
having a higher percentage of patients in remission at the start of the study (Table 14).  Non-
health care and indirect costs were excluded from the analysis. The life years were not adjusted 
by the quality of life (quality-adjusted life years) due to the limitations of the clinical trials and 






 The base case showed that tisagenlecleucel effectiveness was the highest at 19.284, and 
blinatumomab was the second-highest at 12.580. Tisagenlecleuel was cost-effective with an 
ICER of $77,573. Clofarabine was dominated and was the worst out of the three treatment 
strategies for cost-effectiveness. The results of the PSA showed that tisagenlecleucel was always 
not the most cost-effective. Blinatumomab was more cost-effective when it was 35.8% higher 
than the base case. Tisagenlecleuel was more cost-effective at a higher WTP, and blinatumomab 
was more cost-effective at a lower WTP. Tisagenlecleucel was more cost-effective 63.1% of the 
time, and blinatumomab was more cost-effective 35.8% of the time.  
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